TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
TG Therapeutics's price to book ratio was 16.7× on Nov 11, 2026, against 8.5× a year earlier. Over the last 5 years it ranged from 3.6× to 145.0×, with a median of 16.2×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 16.7× | +9.0 |
| 2025 | Dec 31, 2025 | 7.6× | −16.8 |
| 2024 | Dec 31, 2024 | 24.4× | +8.7 |
| 2023 | Dec 29, 2023 | 15.7× | −1.4 |
| 2022 | Dec 30, 2022 | 17.1× | +5.0 |
| 2021 | Apr 30, 2021 | 12.1× | +3.1 |
| 2013 | Apr 30, 2013 | 9.0× | +3.0 |
| 2012 | Dec 31, 2012 | 6.0× | – |
See a number that looks wrong?